Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans

Journal of the American College of Cardiology

Volumn 29, Issue 3, 1997, Pages 479-485

  Wolf, Andreas ^a   Zalpour, Christoff ^a   Theilmeier, Gregor ^a   Wang, Bing Yin ^a   Ma, Adrian ^a   Anderson, Barbara ^a   Tsao, Philip S ^a   Cooke, John P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N ETHYLARGININE; ARGININE; COLLAGEN; NITRIC OXIDE; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

EID: 0031051122     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00523-8     Document Type: Article

References (52)

1. Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinaemia. N Engl J Med 1974;290:434-8.
2. Surya II, Akkerman J-WN. The influence of lipoproteins on blood platelets. Am Heart J 1993;125:272-5.
3. Strano A, Davi G, Averna M, et al. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. Thromb Haemost 1982;48: 18-20.
4. Joist JH, Baker RK, Schonfeld G. Increased in vivo and in vitro platelet function in Type II- and Type IV-hyperlipoproteinemia. Thromb Res 1979;15:95-108.
5. Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989;76:117-24.
6. Andrews HE, Aitkin JW, Hassall DG, Skinner VO, Bruckdorfer KR. Intracellular mechanisms in the activation of human platelets by low-density lipoproteins. Biochem J 1987;242:559-64.
7. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium. Interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:629-36.
8. Simon DI, Stamler JS, Jaraki O, et al. Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb 1993;13:791-9.
9. Fohl U, Busse R. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circ Res 1989;65:1798-1803.
10. Pohl U, Nolle C, Bunse A, Eigenthaler M, Walter U. Endothelium-dependent phosphorylation of vasodilator-stimulated protein in platelets during coronary passage. Am J Physiol 1994;266:8606-12.
11. Verbeuren TJ, Jordaens FH, Zonnekeyn LL, VanHove CE, Coene MC, Herman AG. Effect of hypercholesterolemia on vascular reactivity in the rabbit. Circ Res 1986;58:552-64.
12. Cohen RA, Zitnay KM, Haudenschild CC, Cunningham LD. Loss of selective endothelial cell vasoactive functions caused by hypercholesterolemia in pig coronary arteries. Circ Res 1988;63:903-10.
13. Kugiyama K, Kearns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160-2.
14. Osborne JA, Siegman MJ, Sedar AW, Mooers SU, Lefer AM. Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol-fed rabbits. Am J Physiol 1989;256:591-7.
15. Ludmer PI, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
16. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-34.
17. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.
18. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994;90:35-41.
19. Diodati JG, Cannon RO III, Hussain N, Quyyami AA. Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. Am J Cardiol 1995;75:443-48.
20. Diodati J, Théroux P, Latour J-G, Lacoste L, Lam JYT, Waters D. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. Am J Cardiol 1990;66:683-8.
21. Diodati JG, Cannon RO, Epstein SE, Quyyami AA. Platelet hyperaggregability across the coronary bed in response to rapid atrial pacing in patients with stable coronary artery disease. Circulation 1992;86:1186-93.
22. Girerd XJ, Hirsch AT, Cooke JP, Dzau VJ, Creager MA. L-Arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res 1990;67:1301-8.
23. Cooke JP, Andon NA, Girerd XJ, Hirsch AT, Creager MA. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation 1991;83:1057-62.
24. Rossitch E Jr, Alexander E III, Black PM, Cooke JP. L-Arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J Clin Invest 1991;87:1295-9.
25. Kuo L, Davis MF, Cannon MS, Chilian WM. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation: restoration of endothelium-dependent responses by L-arginine. Circ Res 1992;70:465-76.
26. Creager MA, Girerd XJ, Gallagher SJ, Coleman S, Dzau VJ, Cooke JP. L-Arginine normalizes endothelial response in forearm circulation of hypercholesterolemic humans. J Clin Invest 1992;90:1248-53.
27. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in the coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet 1991;338:1546-50.
28. Tsao PS, Singer AH, Leung LLK, Cooke JP. L-Arginine attenuates platelet reactivity in hypercholesterolemic rabbits. J Arterioscler Thromb 1994;14:1529-33.
29. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-7.
30. Visek WJ. Arginine needs, physiological state and usual diets. A reevaluation. J Nutr 1986;116:36-46.
31. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963;168:178-95.
32. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
33. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest 1994;93:50-5.
34. Minor RL, Myers PR, Guerra R, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990;86:2109-16.
35. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
36. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994;89:2176-82.
37. Drexler H, Fischell TA, Pinto FJ, et al. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients: relation to vessel wall morphology. Circulation 1994;89:1615-23.
38. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorve EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981;57:946-55.
39. Lieberman EH, O'Neill S, Mendelsohn ME. S-Nitrosocysteine inhibition of human platelet secretion is correlated with increases in cGMP levels. Circ Res 1991;68:1722-8.
40. Schafer AI, Alexander RW, Handin RI. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980;55:649-54.
41. Loscalzo J. N-acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985;76:703-8.
42. Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug. Circulation 1988;78:712-6.
43. Eigenthaler M, Nolte C, Halbrügge M, Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Eur J Biochem 1992;205:471-81.
44. Stamler JS, Mendelsohn ME, Amarante P, et al. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989;65: 789-95.
45. Yao SK, Ober JC, Krishnaswami A, et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 1992;86:1302-9.
46. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 1995;125:370-7.
47. Chen LY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets - relevance of the effect of oxidized LDL on platelet function. Circulation 1996;93:1740-6.
48. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer PS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 1995;26:1054-61.
49. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
50. Zhu BQ, Parmley WW. Modification of experimental and clinical atherosclerosis by dietary fish oil. Am Heart J 1990;119:168-78.
51. Fuster V, Bowie EJW, Lewis JC, Fass DN, Owen CA, Brown AL. Resistance to arteriosclerosis in pigs with von Willebrand's disease. J Clin Invest 1978;61:722-30.
52. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992;90:1168-72.